drugset / Trial / NCT03450109

A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer

NCT03450109

Phase 1 Completed 19 enrolled Luye Pharma Group Ltd.
Non-randomizedParallel-groupOpen-labelOther

Summary

A phase I, randomized, open-label and active-control study to assess the PK, PD and safety profiles of LY01005 versus goserelin comparator to be conducted in the USA.

Timeline

Start
2017-12-22
Primary completion
2018-10-15
Completion
2018-10-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Goserelin Other / unclassified 3.6 mg Subcutaneous
Subject LY01005 Unknown 3.6 mg Intramuscular

Indications